What should I do if I develop resistance to Avelumab?

Avelumab (Avelumab) is well tolerated as a single agent or in combination, has a safety profile similar to other anti-PD-1/PD-L1 drugs, and can be used to treat metastatic Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. Based on pharmacokinetics, target occupancy and immunological analysis of dose-escalation trials in solid tumors, avelumab at 10 mg/kg intravenously every 2 weeks was selected as its recommended dose.

Drug resistance is a common problem in drug treatment, especially for cancer patients. During the treatment process, close communication with the doctor should be maintained to keep abreast of changes in the condition so that the treatment plan can be adjusted in a timely manner. When resistance to avelumab occurs, doctors will re-evaluate the patient's condition to understand the specific circumstances of the resistance, such as whether new metastases or disease progression have occurred. The treatment regimen is adjusted based on the specific circumstances of drug resistance. You can consider changing to other drug treatments, or combining them with other treatments such as chemotherapy, radiotherapy, etc.; participate in new clinical trials, explore new treatment options and strategies, and also find more effective ways to deal with drug resistance. Patients should also be encouraged to maintain a positive attitude, cooperate with treatment, and maintain good living and dietary habits to enhance the body's immunity.

Avelumab is an emerging cancer treatment drug. The original drug has not yet been marketed in China, so it cannot be included in medical insurance. The price of Avelumab's generic drug, 200mg/10mL per box, may be more than RMB 10,000 per box (the price may fluctuate due to the exchange rate). We are not aware of any Avelumab generics being produced and put on the market. For specific prices and drug details, please consult Yade's medical consultant.